Metagenomi Announces Positive Preclinical Data for MGX-001

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.Metagenomi, Inc. ( (MGX) ) just unveiled an update. On November 11, 2025, Metagenomi, Inc. announced positive preclinical data from its MGX-001 hemophilia A program, demonstrating curative FVIII activity in non-human primates. The company is prioritizing its MGX-001 program and other advanced therapeutics while reducing its workforce by 25% to extend its cash runway into the fourth quarter of 2027. Jian Irish has been appointed as the new CEO, succeeding Brian Thomas, who remains on the Board. This strategic shift is expected to enhance Metagenomi’s focus on its most promising programs and maintain financial discipline. The most recent analyst rating on (MGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page. Spark’s Take on MGX Stock According to Spark, TipRanks’ AI Analyst, MGX is a Neutral. Metagenomi, Inc. faces significant challenges with profitability and cash flow, which are the most impactful factors on its stock score. The technical analysis further indicates bearish momentum, and the valuation metrics suggest limited attractiveness. These factors combined result in a low overall stock score. To see Spark’s full report on MGX stock, click here. More about Metagenomi, Inc. Metagenomi, Inc. is an in vivo genome editing company that leverages proprietary technologies to develop curative genetic medicines. The company focuses on high-value programs in disease indications with well-understood biology and aims to expand its pipeline using its genetic editing capabilities. Average Trading Volume: 593,096 Technical Sentiment Signal: Sell Current Market Cap: $80.7M Learn more about MGX stock on TipRanks’ Stock Analysis page.